150
Participants
Start Date
May 31, 2022
Primary Completion Date
May 31, 2025
Study Completion Date
December 31, 2026
AZD4205
AZD4205 capsules administered at 150 mg or 75 mg orally, once daily, in 28-day cycle.
RECRUITING
Anhui Provincial Hospital (The First Affiliated Hospital of USTC), Hefei
RECRUITING
The Second Hospital of Anhui Meidcine University, Hefei
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
Peking University Third Hospital, Beijing
RECRUITING
Chongqing Cancer Hospital, Chongqing
RECRUITING
Guangdong Provincial People's Hospital, Guangzhou
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
Hainan General Hospital, Haikou
RECRUITING
Henan Cancer Hospital, Zhengzhou
RECRUITING
Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan
RECRUITING
Hunan Cancer Hospital, Changsha
RECRUITING
Jiangsu Cancer Hospital, Nanjing
RECRUITING
The First Affiliated Hospital of Nanchang University, Nanchang
RECRUITING
The First Bethune Hospital of Jilin University, Changchun
RECRUITING
Shandong Cancer Hospital & Insititution, Jinan
RECRUITING
Ruijing Hospital, Shanghai Jiaotong University School of Medicine, Shanghai
RECRUITING
West China Hospital of Sichuan University, Chengdu
RECRUITING
Tianjin Medical University Cancer Institute & Hospital, Tianjin
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
Lead Sponsor
Dizal Pharmaceuticals
INDUSTRY